BioHarvest Sciences (XTAE:BHST) Cyclically Adjusted Revenue per Share: ₪0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:BHST BioHarvest Sciences Inc XTAE:BHST
50 GF Score
Price ₪5.90
GF Value ₪22.86
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioHarvest Sciences Cyclically Adjusted Revenue per Share?

BioHarvest Sciences XTAE:BHST 50 Cyclically Adjusted Revenue per Share is ₪0.00 as of Jun. 2026. GuruFocus rates XTAE:BHST with a GF Score™ of 50/100 and a GF Value™ of ₪22.86 (Possible Value Trap). The stock has 4 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioHarvest Sciences's adjusted revenue per share for the three months ended in Jun. 2026 was ₪1.190. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₪0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioHarvest Sciences's average Cyclically Adjusted Revenue Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-15), BioHarvest Sciences's current stock price is ₪5.898. BioHarvest Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₪0.00. BioHarvest Sciences's Cyclically Adjusted PS Ratio of today is .

During the past 12 years, the highest Cyclically Adjusted PS Ratio of BioHarvest Sciences was 13.93. The lowest was 1.88. And the median was 8.72.


BioHarvest Sciences  (XTAE:BHST) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of BioHarvest Sciences was 13.93. The lowest was 1.88. And the median was 8.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioHarvest Sciences Cyclically Adjusted Revenue per Share Related Terms


BioHarvest Sciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioHarvest Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioHarvest Sciences Cyclically Adjusted Revenue per Share Chart

BioHarvest Sciences Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioHarvest Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTAE:BHST vs : Cyclically Adjusted Revenue per Share Comparison

For the Packaged Foods subindustry, BioHarvest Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioHarvest Sciences Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioHarvest Sciences's Cyclically Adjusted PS Ratio falls into.


XTAE:BHST
50GF Score
BioHarvest Sciences Inc XTAE:BHST
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioHarvest Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioHarvest Sciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.19/333.9520*333.9520
=1.190

Current CPI (Jun. 2026) = 333.9520.

BioHarvest Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201607 0.000 240.628 0.000
201610 0.000 241.729 0.000
201701 0.000 242.839 0.000
201704 0.000 244.524 0.000
201707 0.000 244.786 0.000
201710 0.000 246.663 0.000
201801 0.000 247.867 0.000
201804 0.000 250.546 0.000
201807 0.000 252.006 0.000
201810 0.000 252.885 0.000
201901 0.000 251.712 0.000
201904 0.000 255.548 0.000
201907 0.000 256.571 0.000
201910 0.000 257.346 0.000
202001 0.000 257.971 0.000
202006 0.011 257.797 0.014
202009 0.013 260.280 0.017
202012 0.066 260.474 0.085
202103 0.079 264.877 0.100
202106 0.103 271.696 0.127
202109 0.158 274.310 0.192
202112 0.172 278.802 0.206
202203 0.164 287.504 0.190
202206 0.197 296.311 0.222
202209 0.354 296.808 0.398
202212 0.586 296.797 0.659
202303 0.496 301.836 0.549
202306 0.626 305.109 0.685
202309 0.737 307.789 0.800
202312 0.983 306.746 1.070
202403 1.187 312.332 1.269
202406 1.125 314.175 1.196
202409 1.151 315.301 1.219
202412 1.282 315.605 1.357
202503 1.385 319.799 1.446
202506 1.500 322.561 1.553
202509 1.589 324.800 1.634
202512 1.295 324.054 1.335
202603 1.146 330.213 1.159
202606 1.190 333.952 1.190

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₪0.00 mean?
BioHarvest Sciences (XTAE:BHST) has a Cyclically Adjusted Revenue per Share of ₪0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioHarvest Sciences and its competitors.
Is BioHarvest Sciences' Cyclically Adjusted Revenue per Share too high?
BioHarvest Sciences' current Cyclically Adjusted Revenue per Share is ₪0.00. Overall, BioHarvest Sciences has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioHarvest Sciences' Cyclically Adjusted Revenue per Share compare to ?
BioHarvest Sciences' Cyclically Adjusted Revenue per Share of ₪0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioHarvest Sciences and its competitors. BioHarvest Sciences's current Cyclically Adjusted Revenue per Share is ₪0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioHarvest Sciences stock overvalued right now?
Based on GuruFocus' analysis, BioHarvest Sciences (XTAE:BHST) is currently considered Possible Value Trap. The stock's GF Value™ is ₪22.86, compared to a current price of ₪5.90 — trading 74.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₪0.00. BioHarvest Sciences' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioHarvest Sciences (XTAE:BHST), the current Cyclically Adjusted Revenue per Share is ₪0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioHarvest Sciences (XTAE:BHST) Overvalued in 2026?

Based on GuruFocus' analysis, BioHarvest Sciences stock appears to be undervalued. The current stock price of ₪5.90 is trading 74.2% below its estimated GF Value™ of ₪22.86. GuruFocus considers BioHarvest Sciences to be Possible Value Trap.

Key valuation signals for XTAE:BHST:

  • Cyclically Adjusted Revenue per Share: ₪0.00
  • GF Value™: ₪22.86 vs. price of ₪5.90 (74.2% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the XTAE:BHST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioHarvest Sciences Business Description

Comparable Companies
Other Exchanges BHST:USA8MV0:Germany
Address 1140-625 Howe Street, Vancouver, BC, CAN, V6C 2T6
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
50GF Score

Get the complete analysis for XTAE:BHST

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪5.90
Price
₪22.86
GF Value